As a proof-of-principle, we targeted one of the nuclear to cytoplasmic transport genes, XPO1, demonstrating its inhibition induced tumor cell death both in vitro and in vivo, in mouse and human MYC-driven cancer cell lines, in a transgenic mouse model of MYC-driven HCC, and in human HCC PDX. This evidence concerns the gene XPO1 and hepatocellular carcinoma.